Autologous chondrocyte implantation (ACI/Autologous chondrocyte implantation) is a method used to treat joint cartilage injury and prevent the onset of post-traumatic osteoarthritis. It has been proven to alleviate pain and promote the recovery of mobility. Typically, ACI involves harvesting cartilage, isolating chondrocytes, expanding cells in vitro, and re implanting in articular cartilage defects. In order to collect a sufficient number of cells for implantation, isolated chondrocytes are typically extensively expanded from 100000 to 200000 to 40 to 60 million. During this period, the cultured chondrocytes gradually lose their proliferative ability and potential to produce cartilage specific matrix, a phenomenon known as dedifferentiation. In addition, the number of senescent cells also increases with the passage of culture time, leading to loss of division ability, loss of resistance to cell apoptosis, and acquisition of a powerful pro-inflammatory secretion group, namely the senescence related secretion phenotype (SASP).
Therefore, selective removal of aging cells from chondrocytes is crucial for ensuring the quality of ACI cells. FOXO4 DRI is a peptide antagonist designed to interfere with the interaction between FOXO4 and p53. Disrupting the interaction between p53 and FOXO4 leads to p53 being excluded from the nucleus and guided into mitochondria to induce apoptosis in senescent cells, ultimately eliminating senescent fibroblasts by triggering apoptosis.
WhatsAPP
E-mail